<DOC>
	<DOC>NCT02095626</DOC>
	<brief_summary>The purpose of this study is to investigate the effect of orally inhaled AP-301 on primary graft dysfunction after lung transplantation.</brief_summary>
	<brief_title>Study in Intensive Care Patients Regarding the Effect of Inhaled AP-301 After Primary Graft Dysfunction After Lung Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Primary Graft Dysfunction</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Being a male or female recipient on the AKH`s waiting list for primary single or double LuTX PGD score â‰¥ 1 within 72 hours after LuTX Informed consent is available History of clinically relevant allergies or idiosyncrasies to AP301 or any other inactive ingredient(s) of the investigational product Postoperative ECMO support Paediatric /adolescent recipients (&lt; 18 years) Lobar transplantation Retransplantation Combined solid organ transplants Participation in other drug trials</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>